Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

There are plenty of drones (and other gadgets) you can buy online that use proprietary control protocols. Of course, reverse-engineering one of these protocols is a hacker community classic. Today, ...

I’m already loving this device, and I haven’t even touched one. Arduino announced it has collaborated with M5Stack to develop the new compact and powerful Nesso N1 IoT development kit. This system ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...

Bristol Myers Squibb is experiencing what many would describe as a pivotal moment as it attempts to balance the strength of its established portfolio with the growing pressure of upcoming patent ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.